Bakker Juliet Tammenoms's Net Worth
Estimate Recalculated Dec 4, 2025 01:11AM EST
Who is Bakker Juliet Tammenoms
Bakker Juliet Tammenoms has an estimated net worth of $8.54 Million. This is based on reported shares across multiple companies, which include CORCEPT THERAPEUTICS INC, COLLEGIUM PHARMACEUTICAL, INC, Esperion Therapeutics, Inc., Inozyme Pharma, Inc., Lexeo Therapeutics, Inc., Axonics Modulation Technologies, Inc., Vera Therapeutics, Inc., RAPID MICRO BIOSYSTEMS, INC., RxSight, Inc., Tricida, Inc., Talaris Therapeutics, Inc., Sierra Oncology, Inc., Vaxcyte, Inc., 89bio, Inc., Eargo, Inc., Kala Pharmaceuticals, Inc., Venus Concept Inc., Molecular Templates, Inc., Aptinyx Inc., and Aimmune Therapeutics, Inc..
SEC CIK
Bakker Juliet Tammenoms's CIK is 0001431159
Past Insider Trading and Trends
2019 was Bakker Juliet Tammenoms's most active year for acquiring shares with 7 total transactions. Bakker Juliet Tammenoms's most active month to acquire stocks was the month of May. 2023 was Bakker Juliet Tammenoms's most active year for disposing of shares, totalling 6 transactions. Bakker Juliet Tammenoms's most active month to dispose stocks was the month of July. 2024 saw Bakker Juliet Tammenoms paying a total of $712,129.30 for 15,554 shares, this is the most they've acquired in one year. In 2023 Bakker Juliet Tammenoms cashed out on 82,293 shares for a total of $2,448,668.49, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
